Aclaris Therapeutics, Inc. ACRS

US Pharmaceuticals

$4.31 ▲ +1.65% (+$0.07)

Open $4.18

Prev Close $4.24

Day Range $4.11 – $4.31

52W Range $2.10 – $6.60

Market Cap $672.52M

Beta 0.93

EPS (TTM) $-0.59

📋 Company Profile

Industry	Pharmaceuticals
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2015-10-07
Shares Out.	147,610,000
Website	aclaristx.com ↗
Phone	13026587581
Employees	73
Revenue	$1.5M
Gross Profit	$1.3M
Net Income	-$18.5M
Free Cash Flow	-$75.3M
Total Assets	$216.2M
Total Liabilities	$49.4M
Equity	$166.8M

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.

Aclaris Therapeutics, Inc. is a publicly traded company under the ticker symbol ACRS on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.